EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The impact of radiometabolic features on the stage and survival in small cell lung cancer

Coskun Dogan, Sedanur Coskun Tok, Sibel Karakaya, Elif Torun Parmaksiz, Ferhan Karatas, Aysenur Toksöz Yildirim, Serkan Güngör, Onur İncealtın, Sacit İçten

Annals of Thoracic Medicine · 2026-07 · 21 (3) · 140-146

DOI: 10.4103/atm.atm_87_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Thoracic Medicine, online erschienen am 03.04.2026. Verfasst von Coskun Dogan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Small-cell lung cancer (SCLC) is a highly aggressive malignancy with a poor prognosis. 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) plays a critical role in staging, as elevated FDG uptake is associated with tumor aggressiveness and metabolic activity. Although radiometabolic parameters such as maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) have been proposed as prognostic markers, existing data remain inconsistent. This study aimed to investigate the association between these parameters and disease stage and overall survival (OS) in SCLC patients. METHODS: Patients diagnosed with lung cancer between May 2022 and June 2023 were retrospectively reviewed and divided into two groups: those with SCLC (Group 1) and those with non-SCLC (Group 2). Demographic, clinical, radiological (thoracic CT), and radiometabolic (PET/CT) features, treatment history, staging, and mortality data (based on the national death registry) were collected. RESULTS: A total of 111 patients (mean age: 65.2 years) were included, of whom 65 (58.6%) had SCLC. In the SCLC group, 55 (85.9%) had extensive-stage disease and 9 (14.1%) had limited-stage disease. Mean SUVmax, MTV, and TLG values were significantly higher in extensive-stage disease (12.5, 87.2, and 624.2, respectively) than in limited-stage disease (7.1, 7.0, and 37.0) ( P < 0.05). Median OS was 12.5 months. Cutoff values for poor prognosis were identified as SUVmax ≥10, MTV ≥40, and TLG ≥170, with significantly shorter OS observed above these thresholds ( P < 0.05). While SUVmax alone was not an independent predictor of survival ( P > 0.05), MTV and TLG were identified as significant prognostic indicators in multivariate analysis ( P < 0.05). CONCLUSION: In SCLC, higher SUVmax values are associated with advanced disease stage. However, MTV and TLG may serve as more reliable independent prognostic biomarkers for survival.

Schlagwörter

Stichwörter der Autor:innen

Fluorodeoxyglucose-positron emission tomography/computed tomographymaximum standardized uptake valuemetabolic tumor volumeprognosissmall-cell lung cancer

Autor:innen und Institutionen

  • Department of Pulmonology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
  • Clinic of Chest Diseases, University of Health Sciences, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, Istanbul, Turkey.
  • Department of Pulmonology, Faculty of Medicine, Koç University, Istanbul, Turkey.
  • Department of Pathology, Istanbul Medeniyet University, Göztepe Training and Research Hospital, Istanbul, Turkey.
  • Department of Nuclear Medicine, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
  • Department of Emergency Medicine, Faculty of Medicine, Istanbul Medeniyet University, Göztepe Training and Research Hospital, Istanbul, Turkey.

Zitieren

APA

Dogan, C., Tok, S. C., Karakaya, S., Parmaksiz, E. T., Karatas, F., Yildirim, A. T., Güngör, S., İncealtın, O., & İçten, S. (2026). The impact of radiometabolic features on the stage and survival in small cell lung cancer. Annals of Thoracic Medicine, 21(3), 140-146. https://doi.org/10.4103/atm.atm_87_25

Vancouver

Dogan C, Tok SC, Karakaya S, Parmaksiz ET, Karatas F, Yildirim AT, et al. The impact of radiometabolic features on the stage and survival in small cell lung cancer. Annals of Thoracic Medicine. 2026;21(3):140-146. doi:10.4103/atm.atm_87_25

BibTeX
@article{Dogan2026,
  author = {Dogan, Coskun and Tok, Sedanur Coskun and Karakaya, Sibel and Parmaksiz, Elif Torun and Karatas, Ferhan and Yildirim, Aysenur Toksöz and Güngör, Serkan and İncealtın, Onur and İçten, Sacit},
  title = {The impact of radiometabolic features on the stage and survival in small cell lung cancer},
  journal = {Annals of Thoracic Medicine},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {140--146},
  doi = {10.4103/atm.atm_87_25}
}
Kostenlos starten →